Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $2.6000 (3.59%) ($2.4800 - $2.6270) on Mon. Feb. 28, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.49% (three month average) | RSI | 45 | Latest Price | $2.6000(3.59%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -0.8% a day on average for past five trading days. | Weekly Trend | HTBX declines -5.2% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Normal for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) EEM(53%) VWO(52%) ONLN(51%) FXI(50%) IPO(50%) | Factors Impacting HTBX price | HTBX will decline at least -2.245% in a week (0% probabilities). VIXM(-57%) VXX(-52%) UUP(-26%) EDOC(-15%) TBT(-14%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.245% (StdDev 4.49%) | Hourly BBV | 1.6 () | Intraday Trend | 4.8% | | | |
|
1 - 5 Day Possible Target | $-7.18(-376.15%) | Resistance Level | $2.73 | 5 Day Moving Average | $2.55(1.96%) | 10 Day Moving Average | $2.65(-1.89%) | 20 Day Moving Average | $2.73(-4.76%) | To recent high | -42.5% | To recent low | 4% | Market Cap | $286m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |